Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Merck Sharp & Dohme LLC
EIR
•Merck Sharp & Dohme LLC•September 20, 2019

Merck Sharp & Dohme LLC – FDA EIR, Sep 20, 2019

Record Details

An FDA inspection was conducted at Merck Sharp & Dohme Corp.'s West Point, PA facility from September 9-20, 2019. As a large licensed biological (vaccine) manufacturer operating under U.S. License No. 002, the inspection followed Compliance Program C.P 7348.858 for Biological Products (Level I, Vaccines), covering Quality, Production, Facilities, and Laboratory Systems. Key deficiencies, resulting in a fifteen-item Form FDA-483, included failures to thoroughly investigate unexplained discrepancies or out-of-specification (OOS) results (e.g., PedvaxHIB), with investigation records lacking complete assessments for adverse events or medical impact. Drug substance bulk deficiencies were not adequately investigated, and Product Quality Complaints and Adverse Event Quality Investigation Reports lacked comprehensive findings. The inspection also identified issues with facility controls, such as inadequate monitoring of temperature-controlled devices, unorganized/unsecured freezers, and deficiencies in environmental monitoring within aseptic processing areas, where the efficacy of disinfectants was not established. Laboratory controls were found lacking scientifically sound specifications, with incomplete data in records and insufficient data review. Additionally, procedures for managing reference standards were inadequate, and qualification validation for walk-in cold rooms used for reserve samples was not performed. The reserve sample program itself was deemed insufficient, with an inadequate sampling plan for annual visual inspections of retained product. Corrective actions are required for these observations.

Company
Merck Sharp & Dohme LLC
Inspection date
September 20, 2019
Product type
biologics
Office
Philadelphia District Office
People
  • Timothy A. McHugh (company_representative)
  • Anissa M. Cheung
  • Heidi P. Lehman (company_representative)
  • Scott E. Norris (issuing_officer)
  • Xiaoshi Wang
View Company Profile

ID · 8e34a33b-4b77-46e3-a555-3cb77cdf99cf

Violation Codes3
21 CFR 820.19821 CFR 21121 CFR 820.100

Full citation text and observation details available on the Dashboard.

Other documents for Merck Sharp & Dohme LLC
  • 483 - 2024-08-23August 23, 2024
  • 483 - 2019-09-09September 9, 2019
  • 483 - 2019-04-30April 30, 2019
  • 483 - 2015-04-17April 17, 2015
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Merck Sharp & Dohme LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.